TRIM-EDICINE
TRIM-edicine is an rapid growing, privately held biotechnology company
Similar Organizations
Vaxine
Vaxine Pty Ltd is a rapidly growing Australian biotechnology company.
Current Advisors List
Current Employees Featured
Founder
More informations about "TRIM-edicine"
Home - TRIM-edicine
Welcome to TRIM-edicine! We are a US biotech company focused on restoring cell health and resilience, with profound initial indications for the treatment of cancers and rare diseases, the protection of multiple organ injuries, and the …See details»
About - TRIM-edicine
TRIM-edicine is an rapid growing, privately held biotechnology company engaged in the development of novel biopharmaceutical products for the treatment of unmet medical needs, including oral healthcare, dermal wounds, …See details»
Leadership - TRIM-edicine
Dr. Jianjie Ma, Ph.D., is the Founder of TRIM-edicine. He holds the Karl P. Klassen Chair of Thoracic Surgery in the Department of Surgery at The Ohio State University (OSU). He is an …See details»
TRIM-edicine - Crunchbase Company Profile & Funding
TRIM-edicine is an rapid growing, privately held biotechnology company engaged in the development of novel biopharmaceutical products for the treatment of unmet medical needs, …See details»
ATAP (Trim-edicine) - Drug Targets, Indications, Patents - Synapse
Nov 21, 2024 ATAP (Trim-edicine), Initially developed by TRIM-edicine, Inc., Now, its global highest R&D status is Pending, Therapeutic Areas: Neoplasms. Biomedical products. Data. …See details»
MG53 (TRIM-edicine) - Drug Targets, Indications, Patents - Synapse
MG53 (TRIM-edicine), Initially developed by TRIM-edicine, Inc., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Nervous System Diseases,Skin and Musculoskeletal …See details»
TRIM-edicine - VentureRadar
TRIM-edicine is an rapid growing, privately held biotechnology company engaged in the development of novel biopharmaceutical products for the treatment of unmet medical needs, …See details»
TRIM-edicine - Contacts, Employees, Board Members
TRIM-edicine is an rapid growing, privately held biotechnology companySee details»
TRIM-edicine Company Profile 2024: Valuation, Funding
TRIM-edicine General Information Description. Developer of protein therapeutics designed for the treatment of human tissue. The company develops novel protein therapeutics and …See details»
TRIM-edicine, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore TRIM-edicine, Inc. with its drug pipeline, therapeutic area, technology platform, 11 literature, Disease Domain:Nervous System Diseases, Technology Platform:Recombinant …See details»
TRIM-edicine Company Profile - Office Locations, Competitors
TRIM-edicine Summary. Company Summary. Overview. TRIM-edicine is a biotechnology company that develops biopharmaceutical products. It offers novel protein therapeutics for …See details»
Trim-Edicine - Products, Competitors, Financials, Employees ...
Trim-Edicine is a biotechnology company specializing in regenerative medicine and therapy. Their main focus is on restoring cell health and resilience, with applications in treating cancers, rare …See details»
TRIM-edicine - Funding, Financials, Valuation & Investors
TRIM-edicine is an rapid growing, privately held biotechnology company. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. ...See details»
Technology - TRIM-edicine
Through either the administration of recombinant MG53 protein or pharmacological modulation of endogenous MG53, TRIM-edicine believes it possesses a potentially important therapeutic …See details»
Recombinant human MG53 protein - TRIM-edicine - AdisInsight
TRIM-edicine is developing recombinant human Mitsugumin53 (MG53) protein for the treatment of muscular dystrophies and ischemia reperfusion. Other potential ... If your organization has a …See details»
MG-29 - Drug Targets, Indications, Patents - Synapse
Last update 14 Nov 2024. MG-29. Last update 14 Nov 2024See details»
Technology - TRIM-edicine
Through either the administration of recombinant MG53 protein or pharmacological modulation of endogenous MG53, TRIM-edicine believes it possesses a potentially important therapeutic …See details»
Mitsugumin29 - AdisInsight
TRIM-edicine is developing a therapy, through either the administration of recombinant Mitsugumin29 (MG29) protein or pharmacological modulation of endogenousSee details»
TRIM-edicine, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Aug 27, 2024 Explore TRIM-edicine, Inc. with its drug pipeline, therapeutic area, technology platform, 10 literature, Disease Domain:Nervous System Diseases, Technology …See details»
News - TRIM-edicine
© 2024 TRIM-edicine. Repairing Life. To TopSee details»